Leadership Under Fire: Turmoil at the FDA

The FDA faces leadership upheaval as acting head Tracey Beth Hoeg plans to depart following Commissioner Marty Makary's resignation. Amidst policy controversies and increased White House oversight, conventional leadership changes are underway. Hoeg led efforts to revise childhood vaccine schedules and reconsider COVID-19 vaccine labeling amidst significant internal disagreements.

The FDA is experiencing a significant leadership shake-up, with acting head Tracey Beth Hoeg planning to leave shortly after Commissioner Marty Makary's resignation. Sources indicate a shift towards more traditional nominees for top health positions as White House oversight increases.

Hoeg, known for her controversial stance on COVID-19 vaccines, had spearheaded changes to the U.S. childhood vaccination schedule, reducing the number of recommended shots from 17 to 11. However, the proposed changes are currently stalled due to a lawsuit on vaccine policy reform.

With Chris Klomp taking a role within the department, more conventional leadership is expected to replace controversial appointees. This shift comes as Robert F. Kennedy's vaccine policy rewrite impacts voter sentiment ahead of the midterm elections, potentially affecting congressional control.